Loading the section
Closing prices for 09 October 2026
Next earnings report: 21 October 2026, after market close · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Medpace Holdings, Inc. trades on Nasdaq under the ticker MEDP. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks MEDP has traded between 373.00 $ and 677.90 $. As of 09 October 2026 the price stood 78.40 % of the way from the 52-week low to the high.
Over one year MEDP shares rose 15.26 %; over six months they rose 24.01 %. Volatility over 90 days is 36.84 %. Dividends are not included: this is price change only, as of 09 October 2026.
MEDP trades at a price-to-earnings ratio of 37.1, above the sector median of 24.8. Price to sales is 6.4, above the sector median of 3.9. Price to book is 28.6, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 602.70 | 620.25 | 602.70 | 612.05 | 159,763 |
| 08 October 2026 | 602.43 | 604.56 | 590.46 | 602.70 | 223,100 |
| 07 October 2026 | 600.00 | 615.63 | 596.08 | 604.25 | 207,600 |
| 06 October 2026 | 624.86 | 642.65 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Medpace runs clinical trials for small biotech companies — end to end, with its own people.
What distinguishes it from large contractors is that the company does not assemble a project from subcontractors but runs it with one team: medical oversight, laboratories, statistics and regulatory dossier preparation in house. For a small developer that matters more than price — it has no specialists of its own, and one mistake costs it the whole programme.
The backlog says more about the future than current revenue does, and the client base makes results sensitive to the availability of venture capital: when money gets dearer, start-ups pause programmes. Risks: biotech funding, cancelled studies and a shortage of research sites. The company pays no dividend but buys back stock actively.
Address:5375 MEDPACE WAY, CINCINNATI, OH, 45227, US
Medpace Holdings, Inc. reported revenue of 2.7B $ and net income of 460M $ over the last four quarters. Net margin is 17.19 %. Revenue changed by +24.19 % year over year. Earnings per share are 15.89 $. Market capitalisation is 17.1B $.
MEDP has a return on equity of 76.95 %, above the sector median of −41.68 %. Return on assets is 21.62 %, above the sector median of −32.11 %. Operating margin is 21.02 %, above the sector median of −26.84 %.
| 160M |
| BIAFbioAffinity Technologies, Inc. | 4.69 | −16.84 % | 67M |
| ABSIAbsci Corporation | 10.14 | +13.37 % | 39M |
| OABIOmniAb, Inc. | 4.79 | +2.79 % | 7M |
| NRCNRC Health | 20.33 | −0.44 % | 3M |
| 601.36 |
| 602.90 |
| 219,100 |
| 05 October 2026 | 601.94 | 623.98 | 601.94 | 620.51 | 341,200 |
| 02 October 2026 | 593.03 | 609.75 | 587.39 | 599.47 | 303,700 |
| 01 October 2026 | 627.47 | 628.60 | 597.37 | 598.08 | 233,400 |
| 30 September 2026 | 622.60 | 628.69 | 614.30 | 624.18 | 306,600 |
| 29 September 2026 | 612.25 | 622.70 | 610.06 | 622.11 | 250,700 |
| 28 September 2026 | 616.16 | 621.62 | 608.05 | 615.94 | 238,700 |
| 25 September 2026 | 620.60 | 620.60 | 608.11 | 618.88 | 229,100 |
| 24 September 2026 | 612.30 | 626.83 | 610.79 | 620.59 | 308,800 |
| 23 September 2026 | 630.06 | 637.65 | 614.18 | 617.15 | 275,700 |
| 22 September 2026 | 624.02 | 632.72 | 619.62 | 630.19 | 303,000 |
| 21 September 2026 | 614.12 | 627.04 | 613.10 | 624.20 | 188,200 |
| 18 September 2026 | 615.41 | 619.41 | 608.54 | 612.33 | 522,200 |
| 17 September 2026 | 620.00 | 622.26 | 608.52 | 615.18 | 225,300 |
| 16 September 2026 | 616.99 | 625.01 | 612.53 | 616.44 | 208,100 |
| 15 September 2026 | 594.30 | 623.03 | 594.08 | 620.48 | 303,900 |
| 14 September 2026 | 595.99 | 600.93 | 589.44 | 595.41 | 201,000 |